# Phase 2 liver cancer trials recruiting: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 2 for liver cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 liver cancer trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/liver-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07919717 | NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919717) |
| November 3, 2026 | NCT07911683 | Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 2 | Not yet recruiting | Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911683) |
| August 28, 2026 | NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Not yet recruiting | Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793253) |
| August 4, 2026 | NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With... | Ruijin Hospital | Phase 2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745790) |
| July 6, 2026 | NCT07685535 | HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Liver Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685535) |
| July 6, 2026 | NCT07684040 | A Study of Combination Therapy in Patients With Resectable Liver Cancer | Affiliated Hospital of Guangdong Medical University | Phase 2 | Not yet recruiting | Liver Cancer (Primary and Metastatic) | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684040) |
| May 14, 2026 | NCT07586046 | Defining the Ablative Dose for Y-90 TARE | Northwestern University | Phase 2 | Recruiting | HCC - Hepatocellular Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586046) |
| March 3, 2026 | NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric (Stomach) Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447050) |
| December 31, 2025 | NCT07312292 | Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312292) |
| November 24, 2025 | NCT07246668 | A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab... | Yonsei University | Phase 2 | Recruiting | Hepatocellular Carcinoma, Liver Neoplasms, Carcinoma, Hepatocellular | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246668) |
| November 24, 2025 | NCT07243951 | Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined... | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243951) |
| November 10, 2025 | NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma, Liver Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226063) |
| November 5, 2025 | NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Breast Cancer, Kidney Neoplasms, Liver Neoplasms | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225114) |
| October 31, 2025 | NCT07223307 | REGULUS: MRI-guided Adaptive SABR for Liver Cancers | Stanford University | Phase 2 | Recruiting | Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223307) |
| August 28, 2025 | NCT07145801 | Y-90 Treatment Response Using Transarterial Radioembolization | Thomas Jefferson University | Phase 2 | Recruiting | HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07145801) |
| August 6, 2025 | NCT07105748 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) | Fudan University | Phase 2 | Recruiting | Mixed Hepatocellular-cholangiocarcinoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105748) |
| April 20, 2025 | NCT06935175 | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06935175) |
| March 3, 2025 | NCT06855225 | A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Combined Hepatocellular and Cholangiocarcinoma | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06855225) |
| February 28, 2025 | NCT06852820 | 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06852820) |
| October 9, 2024 | NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | Beijing Tsinghua Chang Gung Hospital | Phase 2 | Not yet recruiting | Liver Cancer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06632522) |
| August 30, 2024 | NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | University of California, Irvine | Phase 2 | Recruiting | Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580002) |
| August 21, 2024 | NCT06563934 | Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs) | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Liver Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563934) |
| July 9, 2024 | NCT06492408 | Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 | Recruiting | Hepatic Cancer, Surgery | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492408) |
| July 1, 2024 | NCT06482801 | Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 | Recruiting | Liver Cancer, Antibody | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06482801) |
| February 15, 2024 | NCT06261814 | Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors | Sponsor not shown (see the record) | Phase 2 | Recruiting | Liver Neoplasms | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06261814) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai Zhongshan Hospital | 4 |
| University of California, Irvine | 2 |
| Second Affiliated Hospital of Guangzhou Medical University | 2 |
| University of Texas Southwestern Medical Center | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| University College, London | 1 |
| Ruijin Hospital | 1 |
| Thomas Jefferson University | 1 |
| Stanford University | 1 |
| Beijing Tsinghua Chang Gung Hospital | 1 |
| National Cancer Centre, Singapore | 1 |
| Fudan University | 1 |
| Yonsei University | 1 |
| Affiliated Hospital of Guangdong Medical University | 1 |
| Northwestern University | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| China | 8 |
| United Kingdom | 1 |
| Singapore | 1 |
| South Korea | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [Mortgage brokers in the United States](https://specstream.ai/data/businesses/mortgage-brokers/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
- [Psychiatric hospitals in the United States](https://specstream.ai/data/businesses/psychiatric-hospitals/united-states)
- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
